Different angiogenic CXC chemokine levels in bronchoalveolar lavage fluid after interferon gamma-1b therapy in idiopathic pulmonary fibrosis patients

Pulmonary Pharmacology and Therapeutics

Volumn 21, Issue 6, 2008, Pages 840-844

  Antoniou, Katerina M ^a   Tzanakis, Nikolaos ^a   Tzortzaki, Eleni G ^a   Malagari, Katerina ^b   Koutsopoulos, Anastassios V ^c   Alexandrakis, Michael ^c   Wells, Athol U ^d   Siafakas, Nikolaos M ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF CRETE   (Greece)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Angiostasis; CXC chemokines; IFN gamma 1b; Pathogenesis; Treatment

Indexed keywords

ALPHA CHEMOKINE; ANGIOGENIC PROTEIN; ANGIOSTATIC PROTEIN; CXCL1 CHEMOKINE; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GAMMA1B INTERFERON; INTERLEUKIN 8; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PREDNISOLONE; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PROTEIN FUNCTION;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; ANGIOSTATINS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOKINES, CXC; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERFERON-GAMMA, RECOMBINANT; MALE; MIDDLE AGED;

EID: 56949093822     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2008.06.005     Document Type: Article

References (44)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277-304.
2. Bouros D., and Antoniou K.M. Current and future approaches in idiopathic pulmonary fibrosis. Eur Respir J 16 (2005) 693-703
3. King Jr. T.E. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med 172 (2005) 268-279
4. Selman M., King T.E., and Pardo A. American thoracic society; European respiratory society; American college of chest physicians idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134 (2001) 13
5. Antoniou K.M., Pataka A., Bouros D., et al. Pathogenetic pathways and novel therapeutic targets in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 20 (2007) 453-461
6. Antoniou K.M., Ferdoutsis E., and Bouros D. Interferons and their application in the diseases of the lung. Chest 123 (2003) 209-216
7. Ziesche R., Hofbauer E., Wittman K., et al. A preliminary study of long-term treatment with interferon gamma-1b and low -dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med (1999) 1264-1269
8. Raghu G., Brown K.K., Bradford W.Z., et al. Idiopathic pulmonary fibrosis study group. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 350 (2004) 125-133
9. Antoniou K.M., Nicholson A.G., Dimadi M., et al. Long term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J 28 (2006) 496-504
10. Bajwa E.K., Ayas N.T., Schulzer M., et al. Interferon gamma-1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 128 (2005) 203-206
11. Tzortzaki E.G., Antoniou K.M., Zervou M., et al. Effects of antifibrotic agents on TGF-beta1, CTGF and IFN-gamma expression in patients with idiopathic pulmonary fibrosis. Respir Med 101 (2007) 1821-1829
12. Strieter R.M., Starko K.M., Enelow R.I., et al. Effects of interferon gamma-1b on biomarker expression in idiopathic pulmonary fibrosis patients. Am J Respir Crit Care Med 170 (2004) 133-140
13. Park C.C., Morel J.C., Amin M.A., et al. Evidence of IL-18 as a novel angiogenic mediator. J Immunol 167 (2001) 1644-1653
14. Antoniou K.M., Alexandrakis M., Sfiridaki K., et al. Th1 cytokines (IL-12 and IL-18) in bronchoalveolar lavage fluid before and after treatment with interferon gamma-1b or colchicine in idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 21 (2004) 105-110
15. Antoniou K.M., Tzortzaki E.G., Alexandrakis M.G., et al. Investigation of IL-18 and IL-12 in induced sputum of patients with IPF before and after treatment with interferon gamma-1b. Sarcoidosis Vasc Diffuse Lung Dis 22 (2005) 204-209
16. Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 18 (1963) 225-237
17. Strieter R.M., Belperio J.A., and Keane M.P. CXC chemokines in vascular remodeling related to pulmonary fibrosis. Am J Respir Cell Mol Biol 29 (2003) S67-S69
18. Keane M.P., Arenberg D.A., Lynch Jr. J.P., et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 159 (1997) 1437-1443
19. Keane M.P., Belperio J.A., Arenberg D.A., et al. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol 163 (1999) 5686-5692
20. Keane M.P., Belperio J.A., Moore T.A., et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol 162 (1999) 5511-5518
21. Keane M.P., Belperio J.A., Burdick M.D., et al. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 164 (2001) 2239-2242
22. Renzoni E.A., Walsh D.A., Salmon M., et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 167 (2003) 438-443
23. Cosgrove G.P., Brown K.K., Schiemann W.P., et al. Pigment epithelium-derived factor in idiopathic pulmonary fibrosis: a role in aberrant angiogenesis. Am J Respir Crit Care Med 170 (2004) 242-251
24. Ebina M., Shimizukawa M., Shibata N., et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 169 (2004) 1203-1208
25. Renzoni E.A. Neovascularization in idiopathic pulmonary fibrosis: too much or too little?. Am J Respir Crit Care Med 169 (2004) 1179-1180
26. Keane M.P. Angiogenesis and pulmonary fibrosis: feast or famine?. Am J Respir Crit Care Med 170 (2004) 207-209
27. Quanjer P.H., Tammeling G.J., Cotes J.E., et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J 16 Suppl. (1993) 5-40
28. Wells A.U., Hansell D.M., Rubens M.B., et al. The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis. Am Respir Crit Care Med 148 (1993) 1076-1082
29. Wells A.U., King A.D., Rubens M.B., et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am Respir Crit Care Med 155 (1997) 1367-1375
30. Report of the European Society of Pneumonology Task Group 1989.Technical recommendations and guidelines for bronchoalveolar lavage (BAL). Eur Respir J 1989; 2: 561-85.
31. Tzortzaki E.G., Koutsopoulos A.V., Dambaki K.I., et al. Active remodeling in idiopathic interstitial pneumonias (IIPs): evaluation of collagens types XII and XIV. J Histochem Cytochem 54 (2006) 693-700
32. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1 (1995) 27-31
33. Simler N.R., Brenchley P.E., Horrocks A.W., et al. Angiogenic cytokines in patients with idiopathic interstitial pneumonia. Thorax 59 (2004) 581-585
34. Nakayama S., Mukae H., Ishii H., et al. Comparison of BALF concentrations of ENA-78 and IP10 in patients with idiopathic pulmonary fibrosis and non specific interstitial pneumonia. Respir Med 99 (2005) 1145-1151
35. Antoniou K.M., Tzouvelekis A., Alexandrakis M.G., et al. Different angiogenic activity in pulmonary sarcoidosis and pulmonary fibrosis. Chest 130 (2006) 982-988
36. Belperio J.A., Keane M.P., Arenberg D.A., et al. CXC chemokines in angiogenesis. J Leukoc Biol 68 (2000) 1-8
37. Moss M. Clinical year in review II: interstitial lung disease, sepsis, pulmonary infections, and sleep medicine. Proc Am Thorac Soc 4 (2007) 482-488
38. Kao J., Kobashigawa J., Fishbein M.C., et al. Elevated serum levels of the CXCR3 chemokine ITAC are associated with the development of transplant coronary artery disease. Circulation 107 (2003) 1958-1961
39. Strieter R.M., and Keane M.P. Innate immunity dictates cytokine polarization relevant to the development of pulmonary fibrosis. J Clin Invest 114 (2004) 165-168
40. Schroder K., Hertzog P.J., Ravasi T., et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75 (2004) 163-189
41. Antoniou K.M., Tzanakis N., Tzortzaki E.G., et al. Investigation of angiogenetic markers (ENA-78 and GRO-α) in patients with pulmonary sarcoidosis. Eur Respir J 26 Suppl (2005) 49s-79s
42. Strieter R.M. Masters of angiogenesis. Nat Med 11 (2005) 925-927
43. Strieter R.M., Belperio J.A., and Keane M.P. CXC chemokines in angiogenesis related to pulmonary fibrosis. Chest 122 (2002) 298S-301S
44. Strieter R.M., Burdick M.D., Gomperts B.N., et al. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev 16 (2005) 593-609